ImmuCell (FRA:IUL) Common Stock : €0.72 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is ImmuCell Common Stock?

ImmuCell's quarterly common stock declined from Sep. 2023 (€0.73 Mil) to Dec. 2023 (€0.72 Mil) but then increased from Dec. 2023 (€0.72 Mil) to Mar. 2024 (€0.72 Mil).

ImmuCell's annual common stock increased from Dec. 2021 (€0.69 Mil) to Dec. 2022 (€0.74 Mil) but then declined from Dec. 2022 (€0.74 Mil) to Dec. 2023 (€0.72 Mil).

ImmuCell Common Stock Historical Data

The historical data trend for ImmuCell's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Common Stock Chart

ImmuCell Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.66

0.60

0.69

0.74

0.72

ImmuCell Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															0.73	0.72	0.73	0.72	0.72

ImmuCell Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

ImmuCell (FRA:IUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (FRA:IUL) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ICCC:USA

Address

56 Evergreen Drive, Portland, ME, USA, 04103

Website

https://www.immucell.com

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.

ImmuCell (FRA:IUL) Headlines

No Headlines